Immune-Mediated Adverse Effects of Checkpoint Inhibitors: A Clinical Experience

Varování

Publikace nespadá pod Filozofickou fakultu, ale pod Lékařskou fakultu. Oficiální stránka publikace je na webu muni.cz.
Autoři

JUŘICA Jan GONĚC Roman BÁRTOVÁ Adéla GREGOROVÁ Jana

Rok publikování 2022
Druh Článek v odborném periodiku
Časopis / Zdroj European Pharmaceutical Journal
Fakulta / Pracoviště MU

Lékařská fakulta

Citace
www https://sciendo.com/es/article/10.2478/afpuc-2022-0006
Doi http://dx.doi.org/10.2478/afpuc-2022-0006
Klíčová slova Immune checkpoint inhibitors; immunotherapy; adverse effect; autoimmunity
Popis Autoimmune adverse effects of immune checkpoint inhibitors (ICIs) are rare but may be life-threatening. We performed a retrospective analysis of the immune-related adverse effects (irAEs) of ICIs in the Masaryk Memorial Cancer Institute (MMCI) from 2011 to 2021. The ICIs were administered to 648 patients. Severe irAEs were pronounced in 83 patients (12.8%). Further, we report a case of severe irAE after treatment with ipilimumab and nivolumab. Prednisone, mesalazine, octreotide, infliximab, vedolizumab, and mycophenolate mofetil were used to manage G4 colitis, with partial response. Early diagnosis and appropriate management of irAE are essential in the perspective of further oncological treatment.
Související projekty:

Používáte starou verzi internetového prohlížeče. Doporučujeme aktualizovat Váš prohlížeč na nejnovější verzi.